EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study

Joshua Stokar iD, Auryan Szalat

The Journal of Clinical Endocrinology & Metabolism · 18.02.2025 · 110 (3) · e861-e867

DOI: 10.1210/clinem/dgae173 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 14.03.2024. Verfasst von Joshua Stokar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Osteoporosis Center, Hadassah Medical Center, The Hebrew University of Jerusalem, 9124001 Jerus…. Hauptthemen laut MEDLINE: Osteoporosis, Cardiovascular Diseases, Antibodies, Monoclonal, Bone Density Conservation Agents. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Romosozumab, a monoclonal sclerostin antibody, is a recently approved highly potent antiosteoporotic agent with osteoanabolic properties. Clinical use of romosozumab is hindered by the fear of adverse cardiovascular (CV) events raised following the pivotal ARCH trial.

Objective

This work aimed to assess real-world CV safety of romosozumab vs alternative osteoanabolic therapies used for treatment of severe osteoporosis.

Methods

Data were obtained from TriNetX, a global federated health research network including real-time electronic medical records from 113 health care organizations with 136 460 930 patients across 16 countries at time of analysis. Inclusion criteria were age 40 years or older, a diagnosis of osteoporosis and prescription of romosozumab or a parathyroid hormone (PTH) analogue (teriparatide/abaloparatide) during August 2019 through August 2022. Propensity-score-matched cohorts were created 1:1 using demographic variables, comorbidities, and medications. Kaplan-Meier analysis was used to estimate the probability of the outcomes. Outcome measures included incident 3-point major adverse CV event or death (3P-MACE) during 1-year of follow-up after the initial prescription.

Results

A total of 5626 and 15 986 patients met the criteria for romosozumab and PTH analogue cohorts, respectively, with 5610 patients per group following propensity score matching. 3P-MACE was significantly less frequent in the romosozumab vs PTH analogue cohort (158 vs 211 patients with an outcome; P = .003) with reductions in the individual components of the composite outcome: myocardial ischemic events (31 vs 58; P = .003); cerebrovascular events 56 vs 79; P = .037; deaths (83 vs 104; P = .099).

Conclusion

In a diverse, real-world setting, prescription of romosozumab for osteoporosis is associated with fewer adverse CV events when compared to PTH analogue therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisCardiovascular DiseasesAntibodies, MonoclonalBone Density Conservation AgentsTeriparatideHumansFemaleMaleMiddle AgedAgedPropensity ScoreAged, 80 and overCohort StudiesRetrospective StudiesAdultParathyroid Hormone-Related ProteinFollow-Up Studies

Stichwörter der Autor:innen

PTH analoguescardiovascular safetyosteoporosisreal worldromosozumab

Substanzen

romosozumabAntibodies, MonoclonalBone Density Conservation AgentsTeriparatideabaloparatideParathyroid Hormone-Related Protein

Autor:innen und Institutionen

  • Department of Internal Medicine, Faculty of Medicine, Osteoporosis Center, Hadassah Medical Center, The Hebrew University of Jerusalem, 9124001 Jerusalem, Israel.

ORCID-Profile: Joshua Stokar

Zitieren

APA

Stokar, J., & Szalat, A. (2025). Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study. The Journal of Clinical Endocrinology & Metabolism, 110(3), e861-e867. https://doi.org/10.1210/clinem/dgae173

Vancouver

Stokar J, Szalat A. Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study. The Journal of Clinical Endocrinology & Metabolism. 2025;110(3):e861-e867. doi:10.1210/clinem/dgae173

BibTeX
@article{Stokar2025,
  author = {Stokar, Joshua and Szalat, Auryan},
  title = {Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {3},
  pages = {e861--e867},
  doi = {10.1210/clinem/dgae173}
}
Kostenlos starten →